NCT06718205View on ClinicalTrials.gov

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Esophageal Cancer
Interventions
DRUG

Nimotuzumab

Combined chemotherapy phase Nimotuzumab 400mg，I.V.，D1，QW Maintenance treatment period:Until unbearable or PD Nimotuzumab 400mg，I.V.，D1，Q3W

DRUG

Sintilimab

Sintilimab 200mg，I.V.，D1，Q3W，Until unbearable or PD

DRUG

Paclitaxel-albumin

Paclitaxel-albumin 200 mg/m2，I.V.，D1，Q3W，4-6 Cycle

DRUG

Cisplatin

Cisplatin:75 mg/m2，I.V.，D1,Q3W，4-6 Cycle

Trial Locations (1)

450052

RECRUITING

Feng Wang, Zhengzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER